Importance of diagnosis-to-treatment interval in newly diagnosed patients with diffuse large B-cell lymphoma
| Autor: | Katsujun Shimizu, Masahiro Yoshida, Mirei Horiuchi, Yoshiki Hayashi, Hoyuri Fuseya, Minako Tsutsumi, Takeshi Inoue, Takafumi Nakao, Takuro Yoshimura, Yosuke Nakaya, Takahisa Yamane, Naoko Tatsumi |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
Adult
Male medicine.medical_specialty Time Factors Multivariate analysis Science Treatment interval Newly diagnosed Malignancy behavioral disciplines and activities Article Time-to-Treatment 03 medical and health sciences 0302 clinical medicine Internal medicine Antineoplastic Combined Chemotherapy Protocols Humans Medicine Cyclophosphamide Cancer Aged Neoplasm Staging Retrospective Studies Aged 80 and over Multidisciplinary business.industry Middle Aged Prognosis medicine.disease Progression-Free Survival Lymphoma Clinical trial Oncology nervous system Doxorubicin Vincristine 030220 oncology & carcinogenesis Prednisone Female Lymphoma Large B-Cell Diffuse business Diffuse large B-cell lymphoma 030215 immunology |
| Zdroj: | Scientific Reports, Vol 11, Iss 1, Pp 1-7 (2021) Scientific Reports |
| ISSN: | 2045-2322 |
| DOI: | 10.1038/s41598-021-82615-4 |
| Popis: | Treatment of patients with malignancy sometimes be delayed due to various reasons. Several studies revealed that an influence of diagnosis-to-treatment interval (DTI) on outcomes differs depending on the type of malignancy. In this study, we evaluated the influence of DTI on clinical outcomes in newly diagnosed patients with diffuse large B-cell lymphoma (DLBCL). A total of 199 patients were identified with a median DTI of 22 days. At 2 years, patients with short DTI (0–22 days) showed significantly poorer OS (62.7% vs 86.4%) and PFS (55.1% vs 75.9%) compared to those with long DTI (over 22 days). Although short DTI was strongly correlated with several known adverse factors, it remained to be an independent prognostic factor by multivariate analysis. In conclusion, our study confirmed the importance of DTI in patients with DLBCL. Researchers should consider DTI as one of the important prognostic factors and plan clinical trials to be able to enroll patients with aggressive disease requiring urgent treatment. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|